Fulcrum Therapeutics, Inc. (FULC)

Fulcrum Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	80	2.81	6.34	19.16	8.82
Revenue Growth (YoY)	2752.05%	-55.77%	-66.91%	117.19%	-
Cost of Revenue	63.39	71.8	76.78	69.7	59.04
Gross Profit	16.61	-69	-70.44	-50.54	-50.22
Selling, General & Admin	36.45	41.67	41.69	30.52	21.39
Operating Expenses	36.45	41.67	41.69	30.52	21.39
Operating Income	-19.83	-110.66	-112.13	-81.05	-71.61
Interest & Investment Income	12.17	13.33	2.69	0.21	0.79
EBT Excluding Unusual Items	-7.66	-97.34	-109.44	-80.85	-70.82
Merger & Restructuring Charges	-2.06	-	-0.43	-	-
Pretax Income	-9.73	-97.34	-109.87	-80.85	-70.82
Net Income	-9.73	-97.34	-109.87	-80.85	-70.82
Net Income to Common	-9.73	-97.34	-109.87	-80.85	-70.82
Shares Outstanding (Basic)	62	61	45	35	25
Shares Outstanding (Diluted)	62	61	45	35	25
Shares Change (YoY)	1.10%	36.27%	27.23%	39.47%	129.53%
EPS (Basic)	-0.16	-1.59	-2.44	-2.29	-2.79
EPS (Diluted)	-0.16	-1.59	-2.44	-2.29	-2.79
Free Cash Flow	-2.5	-91.47	-99.01	-80.19	-55
Free Cash Flow Per Share	-0.04	-1.49	-2.20	-2.27	-2.17
Gross Margin	20.77%	-	-	-263.73%	-
Operating Margin	-24.79%	-3945.24%	-1768.12%	-422.97%	-811.64%
Profit Margin	-12.16%	-3470.05%	-1732.43%	-421.89%	-802.66%
Free Cash Flow Margin	-3.12%	-3261.07%	-1561.23%	-418.47%	-623.34%
EBITDA	-18.24	-108.49	-109.72	-78.54	-69.23
EBITDA Margin	-22.80%	-	-	-	-
D&A For EBITDA	1.59	2.17	2.41	2.52	2.38
EBIT	-19.83	-110.66	-112.13	-81.05	-71.61
EBIT Margin	-24.79%	-	-	-	-

Updated Feb 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q